Clinical applications of VEGF-Trap (Aflibercept) in cancer treatment

Journal of the Chinese Medical Association

Volumn 73, Issue 9, 2010, Pages 449-456

  Teng, Li Song ^a   Jin, Ke Tao ^a,b   He, Kui Feng ^a   Zhang, Jing ^a   Wang, Hao Hao ^a   Cao, Jiang ^c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Zhuji Hospital   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Angiogenesis; Antiangiogenic agent; Clinical application; VEGF Trap

Indexed keywords

6 (2 AMINOETHYL)AMINO 5 CHLOROURACIL; AFLIBERCEPT; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; GLYCOSYLTRANSFERASE INHIBITOR; PACLITAXEL; TEMOZOLOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; GLIOBLASTOMA; HEPATOBLASTOMA; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; RECOMMENDED DRUG DOSE; REVIEW; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 77957083400     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(10)70097-6     Document Type: Review

References (46)

1. Ferrara N Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
2. Hicklin DJ, Ellis LM Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1127.
3. Folkman J Cancer: Principles and Practice of Oncology 2005, 2865-2882. Lippincott Williams & Wilkins, Philadelphia. 7th edition. V.T. DeVita, S.M.D. Hellman, S.A. Rosenberg (Eds.).
4. Mukhopadhyay D, Datta K Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol 2004, 14:123-130.
5. Wulff C, Wilson H, Wiegand SJ, Rudge JS, Fraser HM Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinol 2002, 143:2797-2807.
6. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 2002, 99:11399-11404.
7. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99:11393-11398.
8. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003, 9:5721-5728.
9. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothe-lial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165:35-52.
10. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003, 100:7785-7790.
11. Fukasawa M, Korc M Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 2004, 10:3327-3332.
12. Kadenhe-Chiweshe A, Papa J, McCrudden KW, Frischer J, Bae JO, Huang J, Fisher J, et al. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res 2008, 6:1-9.
13. Frischer JS, Huang J, Serur A, Kadenhe-Chiweshe A, McCrudden KW, O'Toole K, Holash J, et al. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. Int J Oncol 2004, 25:549-553.
14. Huang J, Frischer JS, New T, Kim ES, Serur A, Lee A, Kadenhe-Chiwishe A, et al. TNP-470 promotes initial vascular sprouting in xenograft tumors. Mol Cancer Ther 2004, 3:335-343.
15. Borgström P, Hillan KJ, Sriramarao P, Ferrara N Complete inhibition of angiogenesis and growth of microtumors by antivascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996, 56:4032-4039.
16. Borgström P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrara N Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998, 35:1-10.
17. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006, 290:H547-H559.
18. Bergers G, Benjamin LE Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
19. Jain RK Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
20. Jain RK Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
21. Kerbel RS Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312:1171-1175.
22. Baka S, Clamp AR, Jayson GC A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 2006, 10:867-876.
23. Dalal S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, Lewis IJ, Johnston C, et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005, 11:2364-2378.
24. Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, Qian DZ, et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007, 13:4201-4208.
25. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 2008, 10:940-945.
26. Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 2008, 7:3747-3758.
27. Lu H, Klein RS, Schwartz EL Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap. Clin Cancer Res 2009, 15:5136-5144.
28. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005, 11:6966-6971.
29. Wachsberger PR, Burd R, Cardi C, Thakur M, Daskalakis C, Holash J, Yancopoulos GD, et al. VEGF trap in combination with radiotherapy improves tumor control in U87 glioblastoma. Int J Radiat Oncol Biol Phys 2007, 67:1526-1537.
30. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, et al. Phase I study of intravenous vascular endothelial growth factor Trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010, 28:207-214.
31. Mulay M, Limentani SA, Carroll M, Furfine ES, Cohen DP, Rosen LS Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors. ASCO Meeting Abstracts 2006, 24:13061.
32. Limentani S, Just R, Purdham A, Mulay M, Bair A, Tamby JF, Chap LI, et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: preliminary results. ASCO Meeting Abstracts 2008, 26:3556.
33. Rixe O, Verslype C, Méric JB, Tejpar S, Bloch J, Crabbe M, Khayat D, et al. Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a combination phase I clinical trial of patients with advanced solid tumors. ASCO Meeting Abstracts 2006, 24:13161.
34. Verslype C, Spano J, Van Cutsem E, Grapin JP, Vandecaveye V, Bloch J, Lazard K Soussan, et al. Validation of the selected dose of aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a phase I clinical trial of patients (pts) with advanced solid tumors (STs): preliminary results. ASCO Meeting Abstracts 2008, 26:14540.
35. Rixe O, Verslype C, Khayat D, Tejpar S, Billemont B, Crabbé M, Méric JB, et al. A phase I dose escalation (DE) and pharmaco-kinetics (PK) study of intravenous aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in patients with advanced solid tumors (STs). ASCO Meeting Abstracts 2008, 26:3557.
36. Isambert N, Freyer G, Zanetta S, Falandry C, Soussan Lazard K, Fumoleau P A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. ASCO Meeting Abstracts 2008, 26:3599.
37. Freyer G, Fumoleau P, You B, Isambert N, Chevalier P, Trillet Lenoir V A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors: preliminary results. ASCO Meeting Abstracts 2008, 26:14539.
38. Patnaik A, Pipas M, Rosen LS, Wood L, Phipps K, Mulay M, Garay C, et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary results. ASCO Meeting Abstracts 2008, 26:3558.
39. Tew WP, Colombo N, Ray-Coquard I, Oza A, del Campo J, Scambia G, Spriggs D VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. ASCO Meeting Abstracts 2007, 25:5508.
40. Colombo N, Mangili G, Mammoliti S, Kalling M, Tholander B, Sternas L, Buzenet G, et al. Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: preliminary results of a pilot study. ASCO Meeting Abstracts 2008, 26:14598.
41. Tang P, Cohen SJ, Bjarnason GA, Kollmannsberger C, Virik K, MacKenzie MJ, Brown J, et al. Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic col-orectal cancer (MCRC): a PMH phase II consortium trial. ASCO Meeting Abstracts 2008, 26:4027.
42. Massarelli E, Miller VA, Leighl NB, Rosen PJ, Albain KS, Hart LL, Melnyk O, et al. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib-resistant adeno-carcinoma of the lung (NSCLA). ASCO Meeting Abstracts 2007, 25:7627.
43. Townsley C, Hirte H, Hoskins P, Buckanovich R, Mackay H, Welch S, Wang L, et al. A phase II study of aflibercept (VEGF trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: a study of the Princess Margaret Hospital Phase II Consortium. ASCO Meeting Abstracts 2009, 27:5591.
44. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath EI, et al. Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic transitional cell carcinoma (TCC) of the urothelium: a California Cancer Consortium trial. ASCO Meeting Abstracts 2009, 27:e16030.
45. Tarhini AA, Christensen S, Frankel P, Margolin K, Ruel C, Shipe-Spotloe J, DeMark M, et al. Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin. ASCO Meeting Abstracts 2009, 27:9028.
46. De Groot JF, Wen PY, Lamborn K, Chang S, Cloughesy TF, Chen AP, DeAngelis LM, et al. Phase II single arm trial of afliber-cept in patients with recurrent temozolomide-resistant glioblas-toma: NABTC 0601. ASCO Meeting Abstracts 2008, 26:2020.